What UFT Treats: Main Uses and Benefits

UFT (Tegafur and Uracil) is commonly used across conditions presenting with systemic or localized discomfort linked to solid malignancies. This medication is applied across domains where additional symptomatic support is needed in conditions marked by increased physiological stress, such as colorectal cancer and gastric cancer.

Addressing Symptoms of Systemic Discomfort

Its primary role is applied across domains where additional symptomatic support is needed, which may contribute to easing the overall symptom load and supports the patient during difficult episodes by easing distress. This approach is relevant for easing symptoms that become more disruptive during flare-ups and that may interfere with daily functioning.

Support After Definitive Treatment

UFT is considered relevant in contexts involving heightened systemic burden after definitive treatment in conditions characterized by periods of heightened symptoms. The treatment is commonly used to help manage symptoms associated with recurrence risk, which helps maintain functional stability and supports general well-being during symptomatic phases.

Assisting with Functional Stability

The oral form is considered relevant for managing symptoms that interfere with daily comfort during treatment. The oral form is relevant for managing symptoms associated with recurrent or episodic manifestations, assisting with maintaining functional stability.

“The oral form is commonly used for managing symptoms associated with recurrent or episodic manifestations, assisting with maintaining functional stability.”

Quick Fact: Supports Symptoms that Interfere with Daily Functioning

Official Eligibility and Non-Eligibility for UFT (Tegafur and Uracil)

Official regulatory documents define strict criteria for populations allowed to use this medicine and groups for whom it is formally contraindicated.

Classification	Population Restriction or Rule
Absolute Contraindications	Complete DPD Deficiency: Patients with known complete lack of Dihydropyrimidine Dehydrogenase (DPD) enzyme activity, due to the risk of severe, life-threatening toxicity from the active drug, must not use UFT.
	Pregnancy and Lactation: Use is contraindicated in pregnant women due to the potential for fetal harm (teratogenicity). It is also contraindicated during breastfeeding.
Age-Related Restrictions	Pediatric Population: Safety and efficacy have not been established in infants, children, or adolescents, resulting in a contraindication for these groups. Use is generally restricted to adult patients (18 years and older).
Conditional Use	Organ Function: The medicine is restricted to use in patients who have adequate liver and kidney function reserves. Use requires caution and close monitoring for those with pre-existing mild to moderate renal or hepatic impairment.
	Reproductive Potential: Male and female patients of reproductive potential are required to use effective contraceptive measures during treatment and for a specified period after the final dose.

Interactions with other medicines and products

Official regulatory documentation establishes specific interaction constraints for UFT (Tegafur and Uracil) concerning certain medicinal products.

Interaction-Related Restrictions and Constraints

Co-administration with a tegafur-gimeracil-oteracil potassium combination product is formally contraindicated due to the risk of severe toxicity. This prohibition is mandatory and requires a 7-day separation period after the combination product has been discontinued to avoid potential adverse outcomes. The regulatory profile also highlights interactions that modify the exposure or effect of co-administered medicines, necessitating careful monitoring.

Official Interaction Statements

Interacting Product Category	Specific Interacting Product	Official Regulatory Statement
Contraindicated Combination	Tegafur-gimeracil-oteracil potassium combination product	Co-administration is formally contraindicated; requires a mandatory 7-day separation following discontinuation.
Co-administered Drug Exposure	Phenytoin	Co-administration requires monitoring due to documented risk of increased Phenytoin plasma concentration.
Coagulation Metrics Alteration	Coumarin anticoagulants (e.g., Warfarin)	Co-administration requires monitoring for alterations in prothrombin time or the International Normalized Ratio (INR).

These official statements define the drug's interaction structure based on absolute prohibitions and clinically significant pharmacokinetic risks. The constraints establish the necessary procedural steps for concurrent use with agents such as Phenytoin and Warfarin, focusing on the mandatory monitoring of specific exposure and coagulation metrics as dictated by regulatory authorities.

The mechanism of UFT (Tegafur and Uracil) relies on a two-part molecular strategy designed to support the generation and protection of its cytotoxic component, followed by multi-level interference with a cell's ability to produce genetic material.

️ Biochemical Modulation and Sustained Drug Exposure

This domain covers the synergy between the two components. The inactive precursor, Tegafur, is converted into the active agent, 5-Fluorouracil (5-FU). Simultaneously, Uracil competitively inhibits the Dihydropyrimidine Dehydrogenase (DPD) enzyme, which is responsible for 5-FU breakdown. This inhibition promotes the sustained systemic exposure of the active component, facilitating its downstream effects.

Disruption of Genetic Synthesis and Integrity

5-FU metabolites define the core mechanism. One key metabolite irreversibly blocks the enzyme Thymidylate Synthase (TS), halting the production of DNA building blocks (dTMP). Furthermore, other metabolites are mistakenly integrated into DNA and RNA structures, causing cellular damage. This sequence of inhibition and structural disruption triggers programmed cell death (apoptosis) and the subsequent reduction in proliferation of rapidly dividing cells.

The usage of UFT (Tegafur and Uracil) is defined by a cyclic administration protocol for the oral hard capsules. The standard daily dose of tegafur is 300 mg/m^2, with the total dose calculated according to the patient’s Body Surface Area (BSA). The capsules are administered in three equally divided doses throughout the day, taken every eight hours. This oral administration method is utilized in the context of advanced cancer therapies.

A key element of the administration protocol is the co-administration of oral calcium folinate (90 mg/day), which is taken concurrently with the UFT capsules. To ensure proper intake, the medicine is swallowed whole with water at least one hour before or one hour after meals.

The treatment follows a 35-day cycle: UFT and calcium folinate are taken for 28 consecutive days, followed by a 7-day rest period. Protocol specifications indicate that if a dose is missed during the 28-day period, it is not to be taken later to compensate. Furthermore, if the UFT regimen is interrupted or reduced, the dose is not increased again for the remainder of the therapy. UFT is contraindicated for children and adolescents under 18 years old.

UFT: Recent Clinical Evidence

Research has explored the clinical utility of UFT (uracil and tegafur combination) in various oncology settings. Clinical studies focus on evaluating its role as a chemotherapy agent, often comparing its effects to other standard treatments or assessing its use in specific patient populations.

Efficacy and Study Design

Evidence primarily stems from randomized controlled trials (RCTs) and meta-analyses. These studies investigated whether UFT, typically combined with other modulators such as leucovorin, was associated with differences in patient outcomes, including disease-free survival and overall survival, compared to established monotherapies or combination regimens. Research has also examined the safety profile and tolerability of UFT when administered over extended periods.

Key Areas of Evaluation:

Area of Research	Primary Endpoint Focus
Adjuvant Treatment	Investigating changes in recurrence risk after surgery.
Metastatic Disease	Evaluating effects on disease progression and survival rates.
Comparative Trials	Assessing differences in efficacy and adverse events compared to fluorouracil or capecitabine.

Combination Therapy and Observational Findings

Studies have assessed UFT as part of a combination regimen to determine if it affected overall clinical response rates when used alongside specific biological agents or radiation therapy. Observational data collected from patient registries and large-scale safety monitoring programs have also been analyzed to better understand the utilization patterns and real-world incidence of associated adverse effects across diverse patient groups.

Key Studies & References

1. NICE Guideline: Colorectal cancer: diagnosis and management (CG131) - Clinical recommendations on chemotherapy regimens
2. UFT: EORTC phase III randomized trial of tegafur-uracil and high-dose leucovorin versus intravenous 5-fluorouracil and high-dose leucovorin in stage III colon cancer

Common questions about UFT (FAQ)

---

Q: Why is UFT prescribed with leucovorin?

A: UFT is officially described as requiring mandatory co-administration with calcium folinate, also known as leucovorin. Regulatory documentation states that the purpose of this combination is for biochemical modulation. This co-administration is intended to modify the activity of the active drug component, 5-fluorouracil.

---

Q: What is the difference between UFT and capecitabine?

A: Both UFT and capecitabine are classified by regulatory bodies as part of the fluoropyrimidine class of chemotherapeutic agents. Official research evidence has examined the use of these two medicines, often comparing their specific administration methods and reported adverse event profiles.

---

Q: Is it normal to have mild nausea when starting UFT?

A: Official regulatory documents classify nausea as a very common adverse reaction associated with UFT use. This means it is classified as occurring in 1 out of 10 people or more. The high frequency indicated in the safety profile provides clarity on the potential for this effect.

---

Q: Is UFT used only for cancer, or does it have other uses?

A: According to official documentation, UFT is classified as an antineoplastic agent, meaning it is a drug used to combat uncontrolled cell growth. Its general purpose is specifically defined as providing systemic antitumor activity, which confirms its designation for this type of use.

---

Q: Is UFT considered a targeted therapy drug?

A: UFT is officially classified as an antineoplastic antimetabolite belonging to the fluoropyrimidine class. This type of drug works by interfering with the production of cellular building blocks, such as genetic material. This classification is distinct from the category known as 'targeted therapy'.

---

Q: What foods or drinks are known to interact with UFT?

A: Official administration instructions specify how UFT must be taken in relation to food to ensure proper intake. It is required that the medicine be swallowed whole with water at least one hour before or one hour after meals. This specific timing relative to meals is required for administration.

---

Q: Is there a risk of interaction between UFT and supplements like Vitamin C or multivitamins?

A: Regulatory documents define specific drug-drug interactions that require mandatory monitoring, such as with phenytoin or warfarin. General vitamins or multivitamins are not listed among the agents with formally defined or restricted interactions in the official documentation.

---

Q: Can I take pain relievers like ibuprofen while on UFT?

A: The official documentation lists only specific medicinal products that require mandatory monitoring for interaction, such as phenytoin and coumarin anticoagulants. Common pain relievers like ibuprofen are not listed among the agents with formally defined or restricted interactions in the official documentation.

---

Q: How does a person's weight affect the use of UFT?

A: Official regulatory guidelines state that the standard daily dose of UFT is calculated based on the patient’s Body Surface Area (BSA). The BSA is a measurement that is derived from both a person's weight and height, meaning weight is a factor in the calculation of the recommended dose.

---

Q: What kind of monitoring tests are usually done while taking UFT?

A: The official safety profile notes that very common adverse reactions involve the Blood and Lymphatic System, including issues like neutropenia and anemia. Regulatory constraints also require monitoring of coagulation metrics (like prothrombin time or INR) when UFT is used alongside coumarin anticoagulants.

---

Q: What is the difference between a UFT capsule and a tablet?

A: The approved dosage form for UFT is defined in official documents as an oral hard capsule. A capsule is a solid dose where the medication is contained within a shell. This differs from a tablet, which is typically a solid, compressed form of the medicine.

---

Q: Can UFT be taken with food, or does it have to be on an empty stomach?

A: Official administration instructions indicate that the medicine must be swallowed whole with water at least one hour before or one hour after meals. This specific timing relative to meals is required for administration.

---

Q: Is UFT still widely used, or is it an older drug?

A: Official documents note that UFT represents a distinct evolution from older intravenous fluorouracil therapies. They also indicate that its dual-component formulation has been widely studied across international medical communities for its systemic antitumor activity.

---

Q: Is there a standard time of day when UFT is usually taken?

A: The required administration protocol dictates that the medicine must be taken in three equally divided doses throughout the day. Official instructions specify that these doses should preferably be taken every eight hours to maintain a consistent spacing.

Storage Requirements

UFT capsules must be stored at Controlled Room Temperature (CRT), defined as 20 C to 25 C (68 F to 77 F). The official labeling permits temperature excursions up to 30 C but prohibits freezing and excessive heat. The product must be stored in its original container to ensure protection from environmental factors, specifically moisture and light, which can compromise the stability of the active ingredients. As with all medicines, the container must be kept out of the sight and reach of children for safety.

Disposal Instructions

Unused or expired UFT capsules must be disposed of in accordance with local requirements for cytotoxic agents. The recommended method is to use a supervised drug take-back program or authorized collection site to ensure proper pharmaceutical waste handling. If take-back options are unavailable and the drug is not on the official flush list, it must be prepared for household trash by mixing the capsules with an undesirable substance, sealing the mixture in a plastic bag, and then discarding the bag.